Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: A single‑center report

Wang,Xueying; Liu,Weiyi; Wang,Mingjing; Fan,Teng; Li,Yumeng; Guo,Xiaoqing; Yang,Xiupeng; Wang,Hongzhi; Xiao,Haiyan; Zhang,Shanshan; Quan,Richeng; Liu,Chi; Tang,Xudong; Lv,Yan; Chen,Zhuo; Li,Liu; Xu,Yonggang; Ma,Rou; Hu,Xiaomei

doi:10.3892/ol.2020.12387

Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: A single‑center report

Authors:
- Xueying Wang
- Weiyi Liu
- Mingjing Wang
- Teng Fan
- Yumeng Li
- Xiaoqing Guo
- Xiupeng Yang
- Hongzhi Wang
- Haiyan Xiao
- Shanshan Zhang
- Richeng Quan
- Chi Liu
- Xudong Tang
- Yan Lv
- Zhuo Chen
- Liu Li
- Yonggang Xu
- Rou Ma
- Xiaomei Hu
View Affiliations

Affiliations: Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. China, Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, P.R. China
Published online on: December 17, 2020 https://doi.org/10.3892/ol.2020.12387
Article Number: 126
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The karyotype is highly important for diagnosis and prognosis in myelodysplastic syndrome (MDS). The objective of the present study was to investigate the cytogenetic characteristics of patients with MDS in China. The karyotypes of 665 Chinese patients with MDS were analyzed, and it was identified that 298 cases (298/665, 44.8%) had abnormal karyotypes. Among the 298 patients with abnormal karyotypes, the 75 patients with trisomy 8 (+8) constituted the most common subset (75/298, 25.2%). The incidence of abnormal karyotypes was significantly higher in patients who were ≥51 years old compared with those <51 years old, (54.8 vs. 34.7%, respectively; P<0.05). Based on World Health Organization (WHO) classification‑based Prognostic Scoring System (WPSS) criteria, the incidence of poor‑prognosis karyotypes was significantly higher (17.4 vs. 5.4%; P<0.05) in the older patient group, and based on the Revised International Prognostic Scoring System (IPSS‑R) criteria, the incidence of poor‑/very poor‑prognosis karyotypes was also significantly higher (17.4 vs. 6.6%; P<0.05) in patients ≥51 years old compared with younger ones. Based on the WHO classification of MDS subtypes, the incidence of abnormal karyotypes in patients with high percentages of bone marrow (BM) blasts [excess blasts (EB)‑I + EB‑II, ≥5% blasts] was significantly higher than that in patients with low percentages of BM blasts (those with single lineage dysplasia + multilineage dysplasia, <5% blasts) (62.5 vs. 36.0%; P<0.05). The incidence of poor‑prognosis karyotypes based on WPSS criteria was significantly higher in patients with high percentages of BM blasts than those with low percentages (22.0 vs. 6.9%, respectively; P<0.05), and the incidence of poor‑/very poor‑prognosis karyotypes based on IPSS‑R criteria was also significantly higher (23.0 vs. 7.4%, respectively; P<0.05). These results demonstrate that +8 is the most common abnormal karyotype in Chinese patients with MDS. Age and the percentage of BM blasts are associated with the incidence of both abnormal karyotypes and karyotypes with poor prognosis. The results of cytogenetic abnormalities in this study will supplement the data on patients of MDS in China.

View Figures

View References

1	Vanlet P, Horny HP, Bennet JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, et al: Definitions and standards in the diagnosis and treatment of myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar
2	AdèS L, Itzykson R and Fenaux P: Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar
3	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar
4	Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 25:3503–3510. 2007. View Article : Google Scholar
5	Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R and Germing U: Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry. Leuk Res. 35:1591–1596. 2011. View Article : Google Scholar
6	Zeidan AM, Shallis RM, Wang R, Davidoff A and Ma XM: Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 34:1–15. 2019. View Article : Google Scholar
7	Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC and Schimmer AD: Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer. 7:118–129. 2007. View Article : Google Scholar
8	Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, et al: New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 30:820–829. 2012. View Article : Google Scholar
9	Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I, Cavigliano PM, Calatroni S, Giardini I, Rocca B, et al: World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol. 137:193–205. 2007. View Article : Google Scholar
10	Xiao Y, Wei J, Chen Y, Zhang KJ, Zhou JF and Zhang YC: Trisomy 8 is the most frequent cytogenetic abnormality in de novo myelodysplastic syndrome in China. Onkologie. 35:100–106. 2012. View Article : Google Scholar
11	Wang H, Wang XQ, Xu XP and Lin GW: Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: A multicenter study. Ann Hematol. 89:535–544. 2010. View Article : Google Scholar
12	Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa JC, et al: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol. 108:346–356. 2000. View Article : Google Scholar
13	Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, et al: Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 106:2633–2640. 2005. View Article : Google Scholar
14	Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, et al: Impact of the degree of anemia on the outcome of patients with myelodysplastic syndromes and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 96:1433–1440. 2011. View Article : Google Scholar
15	Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar
16	Seabright M: A rapid banding technique for human chromosomes. Lancet. 2:971–972. 1971. View Article : Google Scholar
17	Shaffer LG, Slovak ML and Campbell LJ: ISCN: An International System for Human Cytogenetic Nomenclature. S. Karger; Basel: 2009
18	Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B and Wang SA: Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 113:3331–3340. 2008. View Article : Google Scholar
19	Germing U, Gattermann N, Strupp C, Aivado M and Aul C: Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res. 24:983–992. 2000. View Article : Google Scholar
20	Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, Cui J, Chen ZM, Cao Q, Yang G, et al: Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 19:767–775. 2005. View Article : Google Scholar
21	Wu L, Song L, Xu L, Chang C, Xu F, Wu D, He Q, Su J, Zhou L, Xiao C, et al: Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. Tumour Biol. 37:4633–4640. 2016. View Article : Google Scholar
22	Lai YY, Huang XJ, Li J, Zou P, Xu ZF, Sun H, Shao ZH, Zhou DB, Chen FP, Liu ZG, et al: Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China. Leuk Res. 39:530–535. 2015. View Article : Google Scholar
23	Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood. 110:4385–4395. 2007. View Article : Google Scholar
24	Qu S, Xu Z, Zhang Y, Qin T, Cui R and Xiao Z: Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: Results of a single-center study. Leuk Lymphoma. 53:940–946. 2012. View Article : Google Scholar
25	Xu Y, Li Y, Xu Q, Chen Y, Lv N, Jing Y, Dou L, Bo J, Hou G, Guo J, et al: Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. Oncotarget. 8:82475–82490. 2017. View Article : Google Scholar
26	Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP and Tefferi A: Mutations and prognosis in myelodysplastic syndromes: Karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. Am J Hematol. 93:691–697. 2018. View Article : Google Scholar
27	Bernasconi P, Klersy C, Boni M, Cavigliano PM, Giardini I, Rocca B, Zappatore R, Dambruoso I, Calvello C, Caresana M and Lazzarino M: Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Ann Hematol. 89:545–551. 2010. View Article : Google Scholar
28	Willman CL: Molecular genetic features of myelodysplastic syndromes (MDS). Leukemia. 12 (Suppl 1):S2–S6. 1998.
29	Greenberg PL: Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment. Leuk Res. 22:1123–1136. 1998. View Article : Google Scholar
30	Solé F, Luño E, Sanzo C, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Cigudosa JC, Millà F, Ribera JM, et al: Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 90:1168–1178. 2005.
31	Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 113:1351–1361. 2008. View Article : Google Scholar